NCT01023282

Safety and Tolerability Study Evaluating ACR325 in Parkinson's Disease Patients

Randomised, Double-blind, Placebo-controlled Study Evaluating Safety and Tolerability of ACR325 in Parkinson's Disease Patients, With Evaluation of the Effect on Levodopa Induced Dyskinesias as a Secondary Measure

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: NeuroSearch A/S · Industry
• Sex: All
• Age: 30 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The study will evaluate the safety and tolerability of ACR325 in Parkinson disease patients and evaluate the effect on levodopa induced dyskinesias.

Conditions

• Parkinson's Disease
• Tolerability

Interventions

Type	Name	Description
DRUG	ACR325	Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
DRUG	Placebo	Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks

Timeline

• Start date: 2009-11-01
• Primary completion: 2011-04-01
• Completion: 2011-04-01
• First posted: 2009-12-02
• Last updated: 2011-11-02

Locations

2 sites across 1 country: Germany